Cargando…

The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway

Arterial thrombosis and its related diseases are major healthcare problems worldwide. Blebbistatin is an inhibitor of myosin II, which plays an important role in thrombosis. The aim of our study is to explore the effect and potential mechanism of blebbistatin on arterial thrombosis. A ferric chlorid...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuanyuan, Li, Long, Zhao, Yazheng, Han, Han, Hu, Yang, Liang, Di, Yu, Boyang, Kou, Junping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441179/
https://www.ncbi.nlm.nih.gov/pubmed/28539835
http://dx.doi.org/10.7150/ijbs.18485
_version_ 1783238214012633088
author Zhang, Yuanyuan
Li, Long
Zhao, Yazheng
Han, Han
Hu, Yang
Liang, Di
Yu, Boyang
Kou, Junping
author_facet Zhang, Yuanyuan
Li, Long
Zhao, Yazheng
Han, Han
Hu, Yang
Liang, Di
Yu, Boyang
Kou, Junping
author_sort Zhang, Yuanyuan
collection PubMed
description Arterial thrombosis and its related diseases are major healthcare problems worldwide. Blebbistatin is an inhibitor of myosin II, which plays an important role in thrombosis. The aim of our study is to explore the effect and potential mechanism of blebbistatin on arterial thrombosis. A ferric chloride (FeCl(3)) solution at a concentration of 5% was used to induce carotid artery thrombosis in mice. Immunohistochemistry and immunofluorescence staining were used to detect the expression or activation of non-muscle myosin heavy chain IIA (NMMHC IIA), tissue factor (TF), GSK3β and NF-κB. Blebbistatin (1 mg/kg, i.p.) significantly reduced carotid artery thrombosis induced by FeCl(3) solution in mice, inhibited NMMHC IIA expression and impeded TF expression via the GSK3β-NF-κB signalling pathway in mouse arterial vascular tissues. The present study demonstrates that blebbistatin may impede TF expression partly via the Akt/GSK3β-NF-κB signalling pathways in the endothelium in a FeCl(3) model, shedding new insights into the pathogenesis of arterial thrombosis and providing new clues for the development of antithrombotic drugs.
format Online
Article
Text
id pubmed-5441179
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-54411792017-05-24 The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway Zhang, Yuanyuan Li, Long Zhao, Yazheng Han, Han Hu, Yang Liang, Di Yu, Boyang Kou, Junping Int J Biol Sci Research Paper Arterial thrombosis and its related diseases are major healthcare problems worldwide. Blebbistatin is an inhibitor of myosin II, which plays an important role in thrombosis. The aim of our study is to explore the effect and potential mechanism of blebbistatin on arterial thrombosis. A ferric chloride (FeCl(3)) solution at a concentration of 5% was used to induce carotid artery thrombosis in mice. Immunohistochemistry and immunofluorescence staining were used to detect the expression or activation of non-muscle myosin heavy chain IIA (NMMHC IIA), tissue factor (TF), GSK3β and NF-κB. Blebbistatin (1 mg/kg, i.p.) significantly reduced carotid artery thrombosis induced by FeCl(3) solution in mice, inhibited NMMHC IIA expression and impeded TF expression via the GSK3β-NF-κB signalling pathway in mouse arterial vascular tissues. The present study demonstrates that blebbistatin may impede TF expression partly via the Akt/GSK3β-NF-κB signalling pathways in the endothelium in a FeCl(3) model, shedding new insights into the pathogenesis of arterial thrombosis and providing new clues for the development of antithrombotic drugs. Ivyspring International Publisher 2017-05-15 /pmc/articles/PMC5441179/ /pubmed/28539835 http://dx.doi.org/10.7150/ijbs.18485 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Zhang, Yuanyuan
Li, Long
Zhao, Yazheng
Han, Han
Hu, Yang
Liang, Di
Yu, Boyang
Kou, Junping
The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway
title The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway
title_full The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway
title_fullStr The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway
title_full_unstemmed The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway
title_short The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway
title_sort myosin ii inhibitor, blebbistatin, ameliorates fecl3-induced arterial thrombosis via the gsk3β-nf-κb pathway
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441179/
https://www.ncbi.nlm.nih.gov/pubmed/28539835
http://dx.doi.org/10.7150/ijbs.18485
work_keys_str_mv AT zhangyuanyuan themyosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT lilong themyosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT zhaoyazheng themyosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT hanhan themyosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT huyang themyosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT liangdi themyosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT yuboyang themyosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT koujunping themyosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT zhangyuanyuan myosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT lilong myosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT zhaoyazheng myosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT hanhan myosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT huyang myosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT liangdi myosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT yuboyang myosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway
AT koujunping myosiniiinhibitorblebbistatinamelioratesfecl3inducedarterialthrombosisviathegsk3bnfkbpathway